|
For Immediate Release, November 13, 2001 Dr.
Tak Wah Mak joins Board of Directors TORONTO, ONTARIO (November 13, 2001) – Integrative Proteomics, Inc.™ (IPI), a leader in the rapid determination of target function and structure to accelerate the discovery of new medicines, today announced the appointment of Dr. Tak Wah Mak to the Board of Directors. Dr. Mak brings both world-class scientific credentials and industry experience from numerous corporate and scientific advisory boards, and is currently a member of the boards of Lombard Odier Bank of Geneva, Switzerland; the Advisory Board on Cancer Genetics, National Cancer Institute (USA); and Cancer Cell, a new Journal of Cell Press. A University Professor in the Departments of Medical Biophysics and Immunology, University of Toronto, and Vice President of Research and founding Director of the Amgen Institute in Toronto, Dr. Mak received his Ph.D. in Biochemistry from the University of Alberta in 1972, after completing undergraduate and graduate studies at the University of Wisconsin. He is also recipient of several honorary Doctoral degrees including Doctor of Medicine from the University of Zurich. Since 1974, he has been a senior staff scientist at the Ontario Cancer Institute/Princess Margaret Hospital, where, from 1991-1993 he was Head of the Division of Cellular and Molecular Biology. Dr. Mak is the recipient of many honours, including the Gairdner International Prize, King Faisal International Prize for Medicine, the Sloan Prize, General Motors Cancer Research Foundation, and the Novartis Immunology Prize, Novartis Inc. He is a Fellow of the Royal Society, London, and an Officer of the Order of Canada. Dr. John D. Mendlein, Chairman and CEO, said of the appointment: “Dr. Mak brings outstanding scientific and entrepreneurial experience to our Board and we enthusiastically welcome him: a world class scientist who has achieved distinction across a broad range of disciplines, and who also appreciates the fast paced commercial aspects of drug discovery. IPI plans to partner with some of the best companies in the world to design drugs, and Dr. Mak’s scientific expertise and global industry insights will be invaluable to us.” Dr. Aled Edwards, Chief Scientific Officer, Director and a founder of IPI, said: “Dr. Mak’s contributions to the fields of oncology, immunology, genetics and molecular signaling, as well as his seminal research in the field of cancer biology, make him an ideal Board member as IPI continues to enhance its proprietary high-throughput processes and drug discovery programs.” IPI was founded in August, 2000 by Drs. Aled Edwards, Cheryl Arrowsmith and Jack Greenblatt. IPI has raised US $33 million since its inception. The Company’s proprietary Pharmaceutical Proteomics™ platform features mass spectrometry, NMR (nuclear magnetic resonance) spectroscopy and X-ray crystallography technologies from Bruker Daltonics (NASDQ: BDAL), Bruker BioSpin and Bruker AXS, respectively. The Company’s processes enable high throughput target production and the determination of target function and structure to accelerate chemistry. The Company’s Pharmaceutical Proteomics™ Platform also integrates the premier discovery capabilities of Aurora Biosciences to enhance IPI’s internal drug discovery efforts. IPI has more than 60 employees, 70 percent of whom hold advanced degrees. The Company’s investors include the Lombard Odier Immunology Fund, Genesys Capital Partners Inc., and HBM BioVentures (Henri B. Meier, Chairman), as well as industrial partners Aurora Biosciences and the Bruker Companies. For more information, please contact: Integrative
Proteomics, Inc. Contact:
Dr. Joanne E. Harack |